BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Innovent Biologics gets FDA nod to begin Phase 1 trials of oral GLP-1R agonist IBI3032

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...

August 05, 2025 | News

METiS Technologies Secures RMB 400 Million in Series D Funding to Advance AI-Powered Nanodelivery and Accelerate CGT Innovation

METiS Technologies, a global leader in AI-driven nanodelivery innovation, today announced the successful completion of its RMB 400 million Series...

August 05, 2025 | News

WuXi XDC’s New DP3 Facility Achieves GMP Release, Boosting Global Bioconjugate Manufacturing Capacity

WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on t...

August 05, 2025 | News

Chipscreen Biosciences Receives FDA IND Approval for Brain-Penetrant Aurora B Inhibitor CS231295

Shenzhen Chipscreen Biosciences Co., Ltd. ("Chipscreen Biosciences") announced that its wholly owned subsidiary, Chipscreen Biosciences (USA) Ltd., has rec...

August 04, 2025 | News

Everest Medicines Invests US$30.9 Million in I-Mab to Advance Next-Gen Immuno-Oncology Therapies

- Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash in I-Mab. Inclusive of I-MAB shares alread...

August 04, 2025 | News

Mabwell’s CDH17-Targeting ADC 7MW4911 Receives IND Clearance in China and U.S.

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its proprietary CDH17-targeting antibody-drug ...

August 04, 2025 | News

Luye Pharma Begins Phase 1 Trial of Novel Triple-Target Antidepressant LY03021 in China

Luye Pharma Group announced that the first subject has been enrolled in a Phase 1 clinical trial in China for its LY03021, which was filed ...

August 04, 2025 | News

Alphamab Oncology’s Bispecific ADC JSKN022 Clears IND Review in China

Alphamab Oncology announced that the Investigational New Drug (IND) application for JSKN022, an independently developed innovative bispecific antibody-drug...

August 04, 2025 | News

XellSmart Achieves World-First Patient Dosing in Pioneering iPSC-Derived Cell Therapy Trial for Spinal Cord Injury

XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd. achieved a significant milestone in its "world's first" China NMPA & US FDA-approved regis...

July 30, 2025 | News

Tigermed Acquires Japan’s First Imaging CRO Micron to Bolster Asia-Pacific Medical Imaging Capabilities

Tigermed, a leading global provider of clinical research solutions across the full lifecycle of global biopharmaceutical and medical device products, annou...

July 30, 2025 | News

Alphamab Oncology’s HER2-Targeting ADC JSKN003 Secures FDA Orphan Drug Designation for Gastric and GEJ Cancers

Alphamab Oncology announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has been granted Orphan Drug Designation (ODD) by the U.S. Foo...

July 29, 2025 | News

Biocytogen Expands Preclinical Capabilities Across Asia and the U.S. with Over 1,000 Humanized Mouse Models

Biocytogen (HKEX: 02315), an international biotechnology company that drives new drug development with innovative technologies, announced that its pr...

July 29, 2025 | News

Suzhou’s Kintor Pharma Reports Positive Phase II Results for KX-826 in AGA Trial, Clears Path for Phase III

Kintor Pharmaceutical Limited (the "Company") is pleased to announce that the Phase II Stage of the Pivotal Clinical Trial of its in-house developed and po...

July 28, 2025 | News

China’s DualityBio Secures FDA Fast Track for Next-Gen HER3 ADC DB-1310 in Advanced Lung Cancer

DualityBio announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its next-generation HER3-targeting a...

July 23, 2025 | News

Stay Connected